KIA
BMRN icon

Kopp Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kopp Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,015
Closed -$812K – 61
2018
Q1 		$812K Hold
10,015
– – 0.83% 38
2017
Q4 		$893K Sell
10,015
-995
-9% -$86.5K 0.89% 37
2017
Q3 		$1.02M Sell
11,010
-129
-1% -$11.4K 0.94% 34
2017
Q2 		$1.01M Sell
11,139
-44
-0.4% -$4K 0.91% 31
2017
Q1 		$982K Buy
11,183
+85
+0.8% +$7.56K 0.96% 33
2016
Q4 		$919K Sell
11,098
-286
-3% -$24.6K 0.97% 33
2016
Q3 		$1.05M Sell
11,384
-313
-3% -$29.5K 1.04% 28
2016
Q2 		$910K Sell
11,697
-273
-2% -$23.2K 0.48% 39
2016
Q1 		$987K Buy
11,970
+3,246
+37% +$264K 0.54% 34
2015
Q4 		$914K Buy
+8,724
New +$911K 0.45% 38
2013
Q4 		– Sell
-11,691
Closed -$844K – 68
2013
Q3 		$844K Sell
11,691
-1,646
-12% -$109K 0.31% 65
2013
Q2 		$743K Buy
+13,337
New +$831K 0.29% 79

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Kopp Investment Advisors's BMRN Position: Q2 2018 in Review

Kopp Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 10,015 shares — an estimated $812K sold.

Kopp Investment Advisors first reported a position in BMRN in Q2 2013 and held it in 12 quarters. The position peaked at $1.05M in Q3 2016. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Kopp Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Kopp Investment Advisors sold 10,015 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $812K.
  • Kopp Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Kopp Investment Advisors's BioMarin Pharmaceuticals position peaked at $1.05M in Q3 2016.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Kopp Investment Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.